BSPM - reiterates their guidance. Sounds like they changed terms of the Hep B drug - which resulted in lower orders, initially, but much improved cash flow. They claim that ordering improved end of Q3 and that continued into October.... interesting.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.